The Ministry of Health of the Russian Federation has registered Dantrolene (INN Dantrolene), a therapy for malignant hyperthermia. This is evidenced by the information published in the State Register of Medicines (GRLS).
According to the registry, the drug is a lyophilizate for the preparation of an intravenous administration solution, in 20 mg doses. Its shelf life is 2 years.
The registration of the drug attracted attention of “CHEMICAL EXPERT” Telegram channel.
“On 02.03.2022, Dantrolene, the long-awaited drug for malignant hyperthermia, was registered. The manufacturer is OOO Oncotarget, and the holder of the registration certificate is OOO Biserno,” the Telegram channel says.
The deputies asked to register the only drug that saves lives in malignant hyperthermia, back in 2018.
Malignant hyperthermia (HR) is a rare, congenital, life-threatening disorder of calcium transport in skeletal muscles, combined with a hypermetabolic condition and most often triggered by volatile anesthetic agents.